The consistency of these results across heterogeneous real-world populations not only strengthens the case for early GLP-1 RA initiation in patients with incipient renal dysfunction but also underscores the credibility of real-world data for informing therapeutic decisions. The gene discussed is GLP1R; the disease is Abnormal renal physiology.